在与GeneDx合作扩大Niemann-Pick疾病C类的外测序以改进早期诊断和治疗后,Zevra治疗公司的份额上升了19%。 Zevra Therapeutics shares rose 19% after partnering with GeneDx to expand exome sequencing access for Niemann-Pick Disease type C, aiming to improve early diagnosis and treatment.

Zevra Therapeutics股价周二上涨19%，至10.83美元，此前他们宣布与GeneDx合作，扩大对尼曼-皮克病C型（NPC）罕见遗传疾病外显子测序的访问。 Zevra Therapeutics shares jumped 19% to $10.83 on Tuesday after announcing a partnership with GeneDx to expand access to exome sequencing for Niemann-Pick Disease type C (NPC), a rare genetic disorder. 合作的目的是通过增加全美国遗传检测的可用性来改进早期诊断和临床管理。 The collaboration aims to improve early diagnosis and clinical management by increasing availability of genetic testing across the U.S. 这一举动是继Zevra报告2025年的利润率之后采取的,其驱动因素是其NPC治疗(MIPLYFFA)的强劲销售。 The move follows Zevra’s reported profitability in 2025, driven by strong sales of its NPC treatment, MIPLYFFA.